Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 05/02 10:09:21 am
73.2 CHF   --.--%
04/29DJAstraZeneca's Investment Eats Into Profit -- 3rd Update
04/29 NOVARTIS : drug Afinitor® recommended by CHMP for European Union app..
04/29DJAstraZeneca's Investment Eats Into Profit -- 2nd Update
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
04/26/2016 04/27/2016 04/28/2016 04/29/2016 05/02/2016 Date
74.6(c) 74.65(c) 74.8(c) 73.2(c) 73.2 Last
6 172 645 4 135 612 4 712 262 5 677 288 502 109 Volume
-0.13% +0.07% +0.20% -2.14% 0.00% Change
More quotes
Financials ($)
Sales 2016 48 912 M
EBIT 2016 12 816 M
Net income 2016 8 053 M
Debt 2016 14 642 M
Yield 2016 3,72%
Sales 2017 50 474 M
EBIT 2017 13 859 M
Net income 2017 8 993 M
Debt 2017 11 435 M
Yield 2017 3,93%
P/E ratio 2016 21,51
P/E ratio 2017 19,24
EV / Sales 2016 4,47x
EV / Sales 2017 4,27x
Capitalization 204 227 M
More Financials
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, Vaccines & Diagnostics, and Consumer Health.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers surgical,... 
Sector
Pharmaceuticals
Calendar
05/24Shareholder meeting
More about the company
Surperformance© ratings of Novartis AG
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS AG
04/29DJAstraZeneca's Investment Eats Into Profit -- 3rd Update
04/29 NOVARTIS : drug Afinitor® recommended by CHMP for European Union approval to tre..
04/29 NOVARTIS : $28,609 Federal Contract Awarded to Alcon Laboratories
04/29 NOVARTIS : Alcon Research Assigned Patent
04/29DJAstraZeneca's Investment Eats Into Profit -- 2nd Update
04/29DJAstraZeneca's Investment Eats Into Profit
04/29DJAstraZeneca's Investment Eats Into Profit -- Update
04/29 NOVARTIS : Rebecca Leary, Novartis, to Present at 2nd Cancer Markers & Liquid Bi..
More news
Sector news : Pharmaceuticals - NEC
09:08a BAYER : FDA approves Gadavist® injection as first contrast agent in U.S. for use..
08:49aDJValeant's CEO Was Key Force On Pricing -- WSJ
02:38aDJValeant's CEO Was Key Force on Pricing
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/29 Intellia Therapeutics on deck for IPO
04/29 Healthcare ratings roundup
04/29 BLOOMBERG : AstraZeneca, Pfizer among those mulling play for Medivation
04/27 Sunovion's COPD candidate successful in two late-stage studies; NDA planned
04/27 Novartis awarded three BTD tags for Ilaris for rare types of autoinflammatory..


Comments 
Advertisement
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions